Insider Selling: Howard Benjamin Sells 40,000 Shares of Repligen Corp. Stock (RGEN)
Repligen Corp. (NASDAQ:RGEN) VP Howard Benjamin unloaded 40,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $20.34, for a total value of $813,600.00. Following the sale, the vice president now directly owns 73,851 shares in the company, valued at approximately $1,502,129. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Repligen Corp. (NASDAQ:RGEN) traded up 0.89% on Monday, hitting $19.3501. 20,346 shares of the company’s stock traded hands. Repligen Corp. has a 52 week low of $9.41 and a 52 week high of $24.68. The stock has a 50-day moving average of $22.3 and a 200-day moving average of $17.94. The company has a market cap of $631.7 million and a P/E ratio of 37.68.
Repligen Corp. (NASDAQ:RGEN) last issued its quarterly earnings data on Monday, August 11th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was down 10.9% on a year-over-year basis. Analysts expect that Repligen Corp. will post $0.28 EPS for the current fiscal year.
A number of analysts have recently weighed in on RGEN shares. Analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corp. in a research note on Thursday, June 26th. They set a “buy” rating and a $26.00 price target on the stock. Analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.
Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.
Receive News & Ratings for Repligen Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.